12 U.S. IPOs Planned For The Week Of June 16

|
 |  Includes: ARDX, CCS, ECR, FELP, KITE, MCLB, MRKT, PARN, SNDX, VNOM, ZFGN, ZSPH
by: Renaissance Capital IPO Research

The following IPOs are expected to price this week:

Ardelyx (NASDAQ:ARDX), a biotech developing small molecule treatments for kidney and gastrointestinal diseases, plans to raise $50 million by offering 3.6 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Ardelyx would command a market value of $252 million. Ardelyx, which was founded in 2007, booked $31 million in sales over the last 12 months. The Fremont, CA-based company plans to list on the NASDAQ under the symbol ARDX. Citi and Leerink Partners are the joint bookrunners on the deal.

Century Communities (NYSE:CCS), a single-family homebuilder primarily in Colorado, as well as Texas and Nevada, plans to raise $110 million by offering 4.5 million shares at a price range of $23.00 to $26.00. At the midpoint of the proposed range, Century Communities would command a market value of $526 million. Century Communities, which was founded in 2002, booked $287 million in sales over the last 12 months. The Greenwood Village, CO-based company plans to list on the NYSE under the symbol CCS. FBR Capital Markets, J.P. Morgan and Deutsche Bank are the joint bookrunners on the deal.

Eclipse Resources (NYSE:ECR), an oil and natural gas E&P operating in the Appalachian Basin, plans to raise $864 million by offering 30.3 million shares at a price range of $27.00 to $30.00. At the midpoint of the proposed range, Eclipse Resources would command a market value of $4.6 billion. Eclipse Resources, which was founded in 2010, booked $45 million in sales over the last 12 months. The State College, PA-based company plans to list on the NYSE under the symbol ECR. Citi, Goldman Sachs, Morgan Stanley and Barclays are the joint bookrunners on the deal.

Foresight Energy LP (NYSE:FELP), an Illinois Basin coal producer backed by billionaire Christopher Cline, plans to raise $350 million by offering 17.5 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Foresight Energy LP would command a market value of $2.6 billion. Foresight Energy LP, which was founded in 2005, booked $968 million in sales over the last 12 months. The St. Louis, MO-based company plans to list on the NYSE under the symbol FELP. Barclays, Citi, Morgan Stanley and J.P. Morgan are the joint bookrunners on the deal.

Kite Pharma (NASDAQ:KITE), a biotech developing an immunotherapy cancer treatment, plans to raise $78 million by offering 6.0 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Kite Pharma would command a market value of $548 million. Kite Pharma, which was founded in 2009, booked $0 million in sales over the last 12 months. The Santa Monica, CA-based company plans to list on the NASDAQ under the symbol KITE. Jefferies & Co., Credit Suisse and Cowen & Company are the joint bookrunners on the deal.

Markit (NASDAQ:MRKT), the largest provider of bond information and derivatives trade processing, plans to raise $1.1 billion by offering 45.7 million shares at a price range of $23.00 to $25.00. At the midpoint of the proposed range, Markit would command a market value of $4.4 billion. Markit, which was founded in 2003, booked $980 million in sales over the last 12 months. The London, United Kingdom-based company plans to list on the NASDAQ under the symbol MRKT. BofA Merrill Lynch, Barclays, Citi and Credit Suisse are the joint bookrunners on the deal.

Microlin Bio (NASDAQ:MCLB), a diagnostic and therapeutics biotech focusing on microRNA and its role in oncology, plans to raise $30 million by offering 2.7 million shares at a price range of $10.00 to $12.00. At the midpoint of the proposed range, Microlin Bio would command a market value of $76 million. Microlin Bio, which was founded in 2013, booked $0 million in sales over the last 12 months. The New York, NY-based company plans to list on the NASDAQ under the symbol MCLB. Brean Capital and Summer Street Research Partners are the joint bookrunners on the deal.

Parnell Pharmaceuticals Holdings (NASDAQ:PARN), an Australian maker of osteoarthritis and reproductive drugs for dogs, horses and cows, plans to raise $65 million by offering 3.6 million shares at a price range of $17.00 to $19.00. At the midpoint of the proposed range, Parnell Pharmaceuticals Holdings would command a market value of $207 million. Parnell Pharmaceuticals Holdings, which was founded in 1986, booked $12 million in sales over the last 12 months. The Alexandria, Australia-based company plans to list on the NASDAQ under the symbol PARN. Jefferies & Co. and Piper Jaffray are the joint bookrunners on the deal.

Syndax Pharmaceuticals (NASDAQ:SNDX), a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, plans to raise $60 million by offering 4.3 million shares at a price range of $13.00 to $15.00. At the midpoint of the proposed range, Syndax Pharmaceuticals would command a market value of $179 million. Syndax Pharmaceuticals, which was founded in 2005, booked $0 million in sales over the last 12 months. The Waltham, MA-based company plans to list on the NASDAQ under the symbol SNDX. Deutsche Bank and Jefferies & Co. are the joint bookrunners on the deal.

Viper Energy Partners LP (NASDAQ:VNOM), an oil and gas E&P in the Permian Basin spun out of Diamondback Energy, plans to raise $100 million by offering 5.0 million shares at a price range of $19.00 to $21.00. At the midpoint of the proposed range, Viper Energy Partners LP would command a market value of $1.5 billion. Viper Energy Partners LP, which was founded in 2013, booked $31 million in sales over the last 12 months. The Midland, TX-based company plans to list on the NASDAQ under the symbol VNOM. Barclays, Credit Suisse and Wells Fargo Securities are the joint bookrunners on the deal.

Zafgen (NASDAQ:ZFGN), a biotech developing a treatment for severe obesity and hunger-related disorders, plans to raise $75 million by offering 5.0 million shares at a price range of $14.00 to $16.00. At the midpoint of the proposed range, Zafgen would command a market value of $330 million. Zafgen was founded in 2005. The Cambridge, MA-based company plans to list on the NASDAQ under the symbol ZFGN. Leerink Partners and Cowen & Company are the joint bookrunners on the deal.

ZS Pharma (NASDAQ:ZSPH), a late-stage biotech developing a treatment for excess potassium (hyperkalemia), plans to raise $80 million by offering 5.0 million shares at a price range of $15.00 to $17.00. At the midpoint of the proposed range, ZS Pharma would command a market value of $351 million. ZS Pharma, which was founded in 2008, booked $0 million in sales over the last 12 months. The Coppell, TX-based company plans to list on the NASDAQ under the symbol ZSPH. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.

Last week, there were 7 IPO pricings. Abengoa Yield (NASDAQ:ABY), which owns renewable and conventional power and electric transmission assets, was the week's winner, ending up 28% from its IPO price.